



25 April 2013
EMA/CHMP/261823/2013
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion¹ (post authorisation)

Pradaxa

dabigatran etexilate

On 25 April 2013, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Pradaxa. The marketing authorisation holder for this medicinal product is Boehringer Ingelheim International GmbH. They may request a re examination of the CHMP opinion, provided that they notify the European Medicines Agency in writing of their intention within 15 days of receipt of the opinion.

The CHMP adopted a change to a contraindication as follows:

'Lesion or condition, **if considered a at-significant risk factor foref** major bleeding. **This may includesuch-as** current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.'

Detailed conditions for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after the change to the marketing authorisation has been granted by the European Commission.

For information, the full contraindication for Pradaxa will be as follows²:

- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
- Patients with severe renal impairment (CrCL < 30 mL/min) (see section 4.2)
- Active clinically significant bleeding
- Lesion or condition, **if considered a at-significant risk factor foref** major bleeding. **This may includesuch-as** current or recent gastrointestinal ulceration, presence of malignant neoplasms

¹ Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued within 44 days (Type II variations) and 67 days (Annex II applications) from adoption of the opinion.

² The text in bold represents the new or the amended contraindication.



at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.

- Concomitant treatment with any other anticoagulants e.g. unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin etc), heparin derivatives (fondaparinux etc), oral anticoagulants (warfarin, rivaroxaban, apixaban etc) except under the circumstances of switching therapy to or from Pradaxa (see section 4.2) or when UFH is given at doses necessary to maintain an open central venous or arterial catheter (see section 4.5)
- Hepatic impairment or liver disease expected to have any impact on survival
- Concomitant treatment with systemic ketoconazole, cyclosporine, itraconazole, tacrolimus and dronedarone (see section 4.5)
- Prosthetic heart valves requiring anticoagulant treatment (see section 5.1).